What are sporadic primary four‑gland hyperplasia, MEN1 syndrome, and CDC73 mutation, and why does secondary hyperparathyroidism progress?

Understanding Sporadic Primary Four-Gland Hyperplasia, MEN1 Syndrome, CDC73 Mutation, and Secondary Hyperparathyroidism Progression

Sporadic Primary Four-Gland Hyperplasia

Sporadic primary four-gland hyperplasia represents multiglandular clonal proliferation affecting all four parathyroid glands without an identified genetic cause. The terminology has evolved—what was previously called "primary hyperplasia" is now more accurately termed "multiglandular parathyroid disease" because genetic studies have demonstrated these are clonal proliferations rather than true hyperplasia 1. This condition accounts for approximately 15% of primary hyperparathyroidism (PHPT) cases, contrasting with the 80-85% caused by single adenomas 2.

Key distinguishing features include:

• All four glands are enlarged, though not necessarily synchronously
• No identifiable genetic mutation despite thorough testing
• Occurs sporadically without family history
• Typically presents later in life compared to genetic forms

MEN1 Syndrome

MEN1 is an autosomal dominant tumor suppressor gene syndrome causing PHPT in 90-95% of affected patients, typically presenting before age 40 and often between ages 20-25 3.

Genetic Basis

The MEN1 gene (located at 11q13) encodes menin, a 610-amino-acid nuclear protein involved in transcriptional regulation, cell cycle control, and genome stability 4. Pathogenic variants are detected in up to 95% of clinically suspected cases 3. The disease follows Knudson's two-hit tumor suppressor model 4.

Clinical Manifestations

The syndrome is defined by three major lesions:

• PHPT (most frequent, 90-95% penetrance)
• Duodeno-pancreatic neuroendocrine tumors
• Pituitary adenomas

Additional features include bronchial/thymic neuroendocrine tumors, adrenal lesions, skin manifestations (angiofibromas, collagenomas, lipomas), CNS tumors (meningiomas, ependymomas), uterine leiomyomas, and increased breast cancer risk in women 3.

PHPT Characteristics in MEN1

Despite lower serum calcium and PTH levels than sporadic PHPT, MEN1-associated PHPT causes more severe bone and renal complications due to longer disease duration 3:

• Age at onset: Usually <40 years, often 20-25 years (versus 58 years in sporadic PHPT)
• No female predominance (unlike sporadic PHPT)
• Multiglandular involvement with nodular micro-adenomas
• Lower calcium and PTH levels paradoxically associated with worse outcomes
• More severe bone demineralization and recurrent nephrolithiasis 3, 5, 6
• Hypercalcemia may worsen concomitant Zollinger-Ellison syndrome 3

Diagnosis

MEN1 diagnosis requires meeting one of three criteria 3:

1. Clinical: ≥2 major MEN1 manifestations in one individual
2. Familial: MEN1 lesion in first-degree relative of clinical MEN1 patient
3. Genetic: Pathogenic/likely pathogenic MEN1 variant (symptomatic or not)

Screening should begin at age 10 with annual calcium monitoring 3, 7, 8. When genetic testing is negative despite clinical suspicion, evaluate for CDKN1B (MEN4), mosaic MEN1 mutations, or other neuroendocrine tumor genes 3.

Surgical Management

Subtotal parathyroidectomy (removing 3-3.5 glands) performed at expert centers is the recommended approach, balancing cure against hypoparathyroidism risk 3, 9. Total parathyroidectomy with autotransplantation is no longer recommended due to inevitable prolonged hypoparathyroidism 3, 9. Recurrence rates reach 40-60% after subtotal parathyroidectomy, with most patients eventually recurring if followed long enough 9.

CDC73 Mutation (HPT-JT Syndrome)

CDC73 mutations cause Hyperparathyroid-Jaw Tumor (HPT-JT) syndrome, characterized by early-onset severe PHPT (median age 23-38 years), 15-20% risk of parathyroid carcinoma, and ossifying jaw fibromas 3, 10.

Genetic Basis

CDC73 (formerly HRPT2) at 1q31.2 encodes parafibromin, a nuclear protein. Approximately 80% of mutations are truncating, 20% missense 11. The gene functions as a tumor suppressor with autosomal dominant inheritance and 70-90% penetrance 11.

Clinical Features

PHPT in HPT-JT presents with more severe, symptomatic hypercalcemia than sporadic disease 3:

• 90% develop PHPT, often the first manifestation
• Onset as early as age 7-10 years 11
• Usually uniglandular at diagnosis (>70%), though multiglandular involvement possible 11, 3
• 15-20% develop parathyroid carcinoma 11, 3
• 25-50% develop ossifying maxillary/mandibular fibromas 11
• ~75% of women develop uterine tumors (benign and malignant) 11
• ~20% have renal anomalies (cysts, hamartomas, rarely Wilms tumor) 11

Diagnostic Indicators

Loss of nuclear parafibromin staining on immunohistochemistry of any parathyroid tumor in young patients should prompt germline CDC73 testing 11, 1. Atypical parathyroid tumors or carcinomas warrant CDC73 screening 4, 8.

Surveillance

Starting at age 5-10 years 11:

• Annual serum calcium (corrected for albumin)
• Dental panoramic films every 5 years
• Renal ultrasound every 5 years
• Gynecologic assessment with uterine ultrasound as clinically indicated for women 11

Management

Surgery should be discussed at expert centers after comprehensive preoperative workup screening for malignancy and multiglandular disease 3. Biopsy of suspicious neck lesions is discouraged due to seeding risk 11.

Why Secondary Hyperparathyroidism Progresses

Secondary hyperparathyroidism (sHPT) progresses because chronic kidney disease creates a vicious cycle: decreased renal phosphate excretion and reduced 1,25-dihydroxyvitamin D production stimulate continuous PTH secretion, leading to parathyroid hyperplasia that eventually becomes autonomous 2.

Pathophysiologic Progression

The progression follows this algorithmic sequence:

1. Initial stimulus: Chronic kidney disease reduces glomerular filtration
2. Phosphate retention: Decreased renal phosphate excretion → hyperphosphatemia
3. Vitamin D deficiency: Impaired 1α-hydroxylase activity → reduced 1,25(OH)₂D₃ production
4. Hypocalcemia: Low vitamin D → decreased intestinal calcium absorption
5. Compensatory PTH secretion: Parathyroid glands respond appropriately to hypocalcemia and hyperphosphatemia
6. Parathyroid hyperplasia: Chronic stimulation → all four glands enlarge (true hyperplasia, not clonal)
7. Autonomous function: Prolonged hyperplasia → nodular transformation → tertiary hyperparathyroidism with autonomous PTH secretion despite correction of underlying stimuli

Molecular Mechanisms

The WNT/β-catenin signaling pathway activation (through aberrant LRP5 receptor truncation) occurs in the majority of sHPT tumors, representing a common pathway with sporadic parathyroid adenomas 2. Additional mechanisms include:

• CCND1 (cyclin D1) overexpression promoting cell cycle progression
• EZH2 overexpression causing repressive histone modifications
• Accumulation of non-phosphorylated β-catenin
• HIC1 gene repression through histone H3 lysine 27 trimethylation 2

Clinical Implications

Unlike primary hyperparathyroidism where parathyroid tissue is intrinsically abnormal, sHPT initially represents an appropriate physiologic response that becomes pathologic through chronic overstimulation. This explains why:

• All four glands are typically involved (polyclonal hyperplasia initially)
• Medical management targeting the underlying stimuli (phosphate binders, vitamin D analogs, calcimimetics) can be effective early
• Advanced disease may require surgical intervention when autonomous function develops
• The same molecular pathways (β-catenin, cyclin D1) are activated as in primary disease, suggesting convergent mechanisms 2

The key distinction is that sHPT progression is driven by external metabolic derangements rather than intrinsic genetic defects, though the downstream molecular consequences converge on similar pathways.